OncoACP3: A Potential Game-Changer in Prostate Cancer Theranostics —Why?
/in Clinical Trial, Metastatic, Phase 1/by MaxNewsletter 8/2025
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! This time, I welcome you with the Milky Way! This week, we have some exciting updates on cutting-edge treatments in clinical and preclinical trials. I hope you find them as fascinating as I do! I bet you can guess […]
Update: 67Cu-SAR-bisPSMA for mCRPC Has Been Fast-Tracked by FDA
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Dietary Fat and Survival After Nonmetastatic Prostate Cancer September 7, 2026
- Phase 1 Trial: IL‑18–Armored STEAP1 CAR T Cells for Metastatic Castration‑Resistant Prostate Cancer September 7, 2026
- Newsletter 36/2026 September 6, 2026
- De‑escalation therapy in metastatic prostate cancer: can some men safely stop ADT + ARPI after a deep response? September 4, 2026